For U.S. Healthcare Professionals

Questions? Call 855-4ADYNOVATE

Stay Updated

Copay Assistance Program

Do your patients need help paying for ADYNOVATE®?
We’ve Got You Covered

Shire’s CoPay Assistance Program offers financial assistance to eligible patients.

Enrollment is quick and easy for eligible patients. They can call 1-888-229-8379 Mon – Fri, 8:30 a.m. to 8:00 p.m. ET and answer a few simple questions about themselves and their pharmacy to determine eligibility. Shire handles the rest.

Call 1-888-229-8379
Mon – Fri | 8:30 a.m. to 8:00 p.m. ET

Patients can learn more information about the CoPay Assistance Program here.

Click here for full terms and conditions.

Detailed Important Risk Information
Prescribing Information (PI)
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] Important Information
Indications

ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is a human antihemophilic factor indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use

ADYNOVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION


Click here for ADYNOVATE full Prescribing Information.



ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • Control and prevention of bleeding episodes.
  • Perioperative management.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Neutralizing Antibodies
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Click here for ADVATE full Prescribing Information.